诺和诺德公司（Nordisk A/S）在美国法院申请暂时阻止礼来公司（Eli Lilly & Co.）使用声称其药物更强大的广告的请求失败，这对诺和诺德在肥胖症和糖尿病药物市场争夺更大份额的斗争是一次挫败。
Nordisk A/S lost a bid in a US court to temporarily block Eli Lilly & Co. from using s that claim its drugs are more powerful, a setback to Novo as it battles to regain a larger share of the obesity and diabetes drug markets.
美国地区法官扎希德·库拉希（Zahid Quraishi）周一裁定，礼来可以在诺和诺德于七月在新泽西州特伦顿联邦法院提起的诉讼进行期间，继续在其广告中提出有争议的说法。法官表示，诺和诺德申请初步禁令的理由“不够有说服力”，因为其未能证明将遭受无法弥补的损害。
US District Judge Zahid Quraishi ruled Monday that Lilly can continue to make the disputed claims in its ads while Novo proceeds with a lawsuit it filed in July in federal court in Trenton, New Jersey. The judge said that Novo’s case for a preliminary injunction was “less than persuasive” because it failed to show irreparable harm.
这场争议涉及礼来的两组广告。在其中一组中，该制药商声称其肥胖症药物Zepbound优于诺和诺德的减肥药Wegovy。在另一组中，礼来称其Mounjaro控制2型糖尿病的效果优于诺和诺德的Ozempic。该诉讼称，这些比较构成虚假广告，因为礼来依赖的研究并未检验诺和诺德更高剂量的药物，而这些更高剂量的药物比其低剂量药物更有效。
The dispute involves two sets of ads by Lilly. In one, the drugmaker claims its Zepbound obesity drug is superior to Novo’s Wegovy weight-loss medication. In the other, Lilly says its Mounjaro controls type 2 diabetes better than Novo’s Ozempic. The suit claims the comparisons amount to false advertising because Lilly relied on research that didn’t examine higher doses of Novo’s drugs that are more effective than its lower doses.
两家制药商都希望提升其在全球肥胖症治疗市场的份额，彭博智库（Bloomberg Intelligence）估计该市场到2030年每年可能达到1200亿美元。诺和诺德曾凭借Wegovy主导该市场，但礼来凭借Zepbound赶上来，目前在销售上领先。礼来在一份声明中表示，对裁决感到满意。
Both drugmakers seek to boost their share of a global market for obesity treatments that Bloomberg Intelligence estimates could reach $120 billion a year by 2030. Novo once dominated the market with Wegovy, but Lilly caught up with Zepbound and now has the lead in sales. Lilly said in a statement that it was pleased with the ruling.
“我们的关注点一直是，并且将继续是，数以百万计患有肥胖症、2型糖尿病及其他慢性疾病的人，”这家总部位于印第安纳波利斯的公司表示。诺和诺德未立即回应置评请求。
“Our focus has been and continues to be on the millions of people living with obesity, type 2 diabetes, and other chronic diseases,” the Indianapolis-based company said. Novo didn’t immediately respond to a request for comment.